Avista picks up OTC drug developer Wellspring from Audax

‘The diversified and highly established nature of WellSpring’s product portfolio, coupled with a strong innovation pipeline and exciting growth opportunities in e-commerce, was very compelling,’ said Avista’s Yu.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this